# A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy

> **NCT06528093** · PHASE1 · TERMINATED · sponsor: **Boehringer Ingelheim** · enrollment: 8 (actual)

## Conditions studied

- Pancreatic Ductal Adenocarcinoma

## Interventions

- **DRUG:** BI 765883
- **DRUG:** gemcitabine
- **DRUG:** nab-paclitaxel

## Key facts

- **NCT ID:** NCT06528093
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-10-16
- **Primary completion:** 2025-03-19
- **Final completion:** 2025-06-19
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Primary endpoint not met
- **Last updated:** 2026-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06528093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06528093, "A Study to Find a Suitable Dose of BI 765883 and to Test Whether it Helps People With Advanced Pancreatic Cancer When Taken Alone or Together With Chemotherapy". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT06528093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*